Moderna's Q4 revenue falls 30% to $678 million

 Moderna Inc. revealed on Friday that its total revenue in the fourth quarter of fiscal 2025 declined 30% year-on-year to $678 million, driven mainly by lower COVID-19 vaccine sales. The figure came in at "the higher end of the Company's prior expectations."

For the quarter, Moderna posted a net loss of $826 million, compared to the $1.1 billion loss a year earlier, while diluted loss per share improved to $2.11 from $2.91. For the full year, revenue fell 40% to $1.9 billion, with a net loss of $2.8 billion and diluted loss per share of $7.26.

"In 2025, we sharpened our commercial execution, launched our third product and brought online three international manufacturing sites, while advancing our mRNA pipeline," CEO Stephane Bancel said, adding the company aims for up to 10% revenue growth in 2026 alongside further expense reductions.

Shares of Moderna were down 2.14% in the premarket trading to sell at $39.25 after the release of the report.

https://breakingthenews.net/Article/Moderna's-Q4-revenue-falls-30-to-dollar678-million/65666602